CANF 2.44 Can-Fite Biopharma Ltd Sponsore $CANF Hi
Post# of 88
Posted On: 11/12/2014 11:05:33 AM
CANF 2.44 Can-Fite Biopharma Ltd Sponsore $CANF Hit a 52 week low of 2.39 Closing the day 10:41 at 2.44 -0.21 -7.92% With a day low of 2.39 and a total volume of 18,251.
CANF Recent Posts: http://investorshangout.com/Can-Fite-Biopharm...ANF-88432/
CANF Can-Fite Biopharma Ltd Sponsore Recent Headline News
Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST
CANF: 2.44 (-0.21), JNJ: 108.54 (-0.37), IDRA: 2.50 (-0.08), DERM: 16.03 (unch), MRK: 59.28 (-0.09), PFE: 30.38 (+0.06), AZN: 74.17 (-0.03), AMGN: 161.31 (-1.11), GSK: 45.67 (-0.29), HSP: 57.69 (+0.38), NVS: 92.90 (+0.13), CELG: 107.32 (-0.53)
Can-Fite to Participate in BIO-Europe International Partnering Conference
PR Newswire - Thu Oct 30, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that the Company's CEO, Dr. Pnina Fishman and its Director of Business Development, Dr. Sari Fishman, will participate in approximately 40 scheduled one-on-one meetings with potential industry partners at BIO-Europe® in Frankfurt, Germany on November 3 to 5, 2014.
CANF: 2.44 (-0.21)
Ad Comm backs approval of secukinumab
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 6:32AM CDT
CANF: 2.44 (-0.21), JNJ: 108.54 (-0.37), IDRA: 2.50 (-0.08), DERM: 16.03 (unch), PFE: 30.38 (+0.06), AZN: 74.17 (-0.03), MRK: 59.28 (-0.09), AMGN: 161.31 (-1.11), HSP: 57.69 (+0.38), CELG: 107.32 (-0.53), NVS: 92.90 (+0.13)
Ad Comm meeting approaches for Novartis' psoriasis therapy candidate
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 10:46AM CDT
CANF: 2.44 (-0.21), JNJ: 108.54 (-0.37), IDRA: 2.50 (-0.08), DERM: 16.03 (unch), PFE: 30.38 (+0.06), AZN: 74.17 (-0.03), MRK: 59.28 (-0.09), AMGN: 161.31 (-1.11), HSP: 57.69 (+0.38), CELG: 107.32 (-0.53), NVS: 92.90 (+0.13)
Corcept Therapeutics (CORT) Jumps: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 8:32AM CDT
Corcept Therapeutics Incorporated (CORT) was a big mover last session, as the company saw its shares rise more than 6% on the day.
CANF: 2.44 (-0.21), AMPE: 3.37 (-0.26), CEMP: 14.03 (-0.02), CORT: 3.01 (-0.06)
Can-Fite CEO Dr. Pnina Fishman to Co-Chair and Present at the 19th World Congress on Advances in Oncology's Cancer Therapeutics Session
PR Newswire - Tue Oct 07, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced the Company's CEO, Dr. Pnina Fishman, will co-chair the Cancer Therapeutics session of the 19th World Congress on Advances in Oncology. The conference will take place in Athens, Greece, from October 9-11, 2014.
CANF: 2.44 (-0.21)
U.S. Patent and Trademark Office Issues Can-Fite Patent for CF102 in the Treatment of Liver Regeneration and Function Following Surgery
PR Newswire - Tue Sep 30, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced the United States Patent and Trademark Office has issued a patent to the Company which covers its drug candidate, CF102, in the treatment of liver regeneration and function following liver surgery. The issued patent # 8,846,635 is titled, "Method for inducing hepatocyte proliferation and uses thereof." Can-Fite has recently been granted a patent for this technology in Japan and the European Union.
CANF: 2.44 (-0.21)
Can-Fite Files June 30, 2014 Interim Financial Statements
PR Newswire - Wed Sep 17, 2:02PM CDT
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has filed its unaudited interim consolidated financial statements as of June 30, 2014 and an operating and financial review for such period with the U.S. Securities and Exchange Commission. The filing can be found on the company's website at www.canfite.com as well as on the SEC website at www.sec.gov.
CANF: 2.44 (-0.21)
Can Fite's Drug CF101 is Presented in Scientific Journal as One of Four Small Molecule Drugs for the Treatment of Psoriasis
PR Newswire - Wed Sep 17, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that an article titled, "New Drugs and Treatment Targets in Psoriasis," published in the peer-reviewed scientific journal Acta Derm Venereologica, cites the Company's CF101 as a potential treatment for psoriasis. The article was written by researchers at the Department of Dermato-allergology, Gentofte Hospital, University of Copenhagen, Denmark. To read the article in full, please visit: Acta Derm Venereologica.
CANF: 2.44 (-0.21)
Uveitis Therapeutics Pipeline Review, H2 2014 - 19 Companies & 30 Drug Profiles
M2 - Tue Sep 09, 8:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cv63wn/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - pSivida Corp. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Apitope International NV - Novartis AG - Pfizer Inc. - Enzo Biochem, Inc. - Can-Fite BioPharma Ltd. - XOMA Corporation - HanAll Biopharma Co., Ltd. - TxCell SA - Endocyte, Inc. - to-BBB technologies BV - Janssen Biotech, Inc. - Icon Bioscience, Inc. - Eleven Biotherapeutics - AbbVie Inc. - OncoNOx ApS - Panoptes Pharma Ges.m.b.H. Drug Profiles - sirolimus - adalimumab - fluocinolone acetonide - gevokizumab - secukinumab - CF-101 - triamcinolone acetonide - LFG-316 - B27-PD - triamcinolone acetonide - celecoxib - HL-036 - EC-1496 - PA-2612 - 2B3-201 - ATX-UV1 - ATX-UV2 - Stem Cell Therapy for Ophthalmic and Autoimmune Diseases - OX-1001 - P-13 - IBI-70090 - plastoquinone decyl triphenylphosphonium bromide - EC-1669 - lodamin - PP-001 - INV-17 - EBI-028 - Col-Treg - Small Molecules to Inhibit Kinase for Uveitis and IBD - Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Metabolic, Respiratory and Autoimmune Disorders For more information visit http://www.researchandmarkets.com/research/cv63wn/uveitis
CANF: 2.44 (-0.21), ECYT: 6.46 (+0.21), ENZ: 4.93 (+0.01), PFE: 30.38 (+0.06), ABBV: 63.69 (-0.16), XOMA: 4.00 (-0.04), NVS: 92.90 (+0.13)
Can-Fite BioPharma receives Japanese patent for liver regeneration clinical stage drug candidate CF102
M2 - Mon Sep 08, 5:27AM CDT
Biotechnology company Can-Fite BioPharma (NYSE MKT:CANF) (Tel Aviv:CFBI.TA) reported on Friday the receipt of the patent, titled 'Method for inducing hepatocyte proliferation and uses thereof', from the Japanese Patent Office.
CANF: 2.44 (-0.21)
Can-Fite Issued Japanese Patent for CF102 in the Treatment of Liver Regeneration and Function Following Surgery
PR Newswire - Fri Sep 05, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced the issuance of Patent No. 2010-529501, titled, "Method for inducing hepatocyte proliferation and uses thereof," by the Japanese Patent Office. The patent covers Can-Fite's clinical stage drug candidate, CF102, in the treatment of liver regeneration and function following liver surgery or other injury via inhibition of pro-apoptotic proteins, resulting in liver repair. A European Patent (No. 2227234) for this technology was issued earlier this year in the European Union.
CANF: 2.44 (-0.21)
Can-Fite posts lower loss of USD3.59m for first six months 2014
M2 - Wed Sep 03, 7:21AM CDT
Biotechnology company Can-Fite BioPharma (NYSE MKT:CANF) (Tel Aviv:CFBI.TA) on Tuesday declared a loss of USD3.59m for the six months ended 30 June 2014.
CANF: 2.44 (-0.21)
Can-Fite to Present at Rodman & Renshaw Global Investment Conference in New York City on September 9, 2014
PR Newswire - Wed Sep 03, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today the Company's CEO, Dr. Pnina Fishman, will present at the Rodman & Renshaw 16th Annual Global Investment Conference which will take place at the New York Palace Hotel in New York City on September 8th through 10th, 2014. Dr. Fishman is scheduled to present at 11.40 am on Tuesday, September 9th.
CANF: 2.44 (-0.21)
Can-Fite Reports First Six Months 2014 Results
PR Newswire - Tue Sep 02, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported financial results for the six months ended June 30, 2014 and updates on its clinical programs.
CANF: 2.44 (-0.21)
New Data Shows High Efficacy for Can-Fite's CF101 in Rheumatoid Arthritis and Psoriasis Patients
PR Newswire - Wed Aug 06, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today new data from a retrospective analysis of its autoimmune disease advanced trials that shows high efficacy of its orally bioavailable drug CF101.
CANF: 2.44 (-0.21)
Chronic Plaque Psoriasis - Pipeline Review, H1 2014
M2 - Wed Jul 30, 3:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dpkjk3/chronic_plaque) has announced the addition of the "Chronic Plaque Psoriasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Plaque Psoriasis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Plaque Psoriasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - AbGenomics International, Inc. - AbbVie Inc. - Actelion Ltd - Almirall, S.A. - ApoPharma Inc. - Biotest AG - Boehringer Ingelheim GmbH - Can-Fite BioPharma Ltd. - Eli Lilly and Company - GlaxoSmithKline plc - Incyte Corporation - Merck & Co., Inc. - Novartis AG - OPKO Health, Inc. - Pfizer Inc. - Sandoz Inc. For more information visit http://www.researchandmarkets.com/research/dp...nic_plaque
CANF: 2.44 (-0.21), OPK: 8.34 (-0.19), PFE: 30.38 (+0.06), MRK: 59.28 (-0.09), INCY: 70.82 (-0.24), LLY: 67.54 (-0.31), ABBV: 63.69 (-0.16), GSK: 45.67 (-0.29), NVS: 92.90 (+0.13)
Can-Fite CEO to Deliver Scientific Presentation and Serve on Expert Panel at Purines 2014 in Bonn, Germany on July 23-27, 2014
PR Newswire - Mon Jul 21, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today the Company's CEO and Chief Science Officer, Dr. Pnina Fishman, will participate in Purines 2014. The international conference on nucleotides, nucleosides and nucleobases, is to be held in Bonn, Germany, from July 23-27, 2014. Purines 2014 will bring together the leading international scientists in the field. At this year's conference aspects of the molecular and cellular biology of purinergic signaling will be covered as well as its role in the physiology and pathology of various organ systems and the development of novel strategies for drug development and therapy.
CANF: 2.44 (-0.21)
Can-Fite's CF102 Approved for Compassionate Use in Israel for Liver Cancer Patient
PR Newswire - Thu Jul 10, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Israeli Ministry of Health (MOH) has approved the use of its drug CF102 for a patient with hepatocellular carcinoma, the most common form of liver cancer, under the country's Compassionate Use Program. The program allows doctor-initiated single-patient access to investigational treatments for innovative or investigational products not yet registered in any country worldwide. Can-Fite has also previously received Orphan Drug Designation from the U.S. Food and Drug Administration for CF102 in the treatment of advanced hepatocellular carcinoma.
CANF: 2.44 (-0.21)
Can-Fite to Exhibit at Bio International Convention in San Diego on June 23 - 26, 2014
PR Newswire - Thu Jun 19, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today the Company will exhibit at the Bio International Convention in San Diego on June 23rd through 26th, 2014 at the Israel Office of the Chief Scientist's booth #611. The Company's CEO, Dr. Pnina Fishman and its Director of Business Development, Dr. Sari Fishman will conduct one-on-one meetings with potential partners, as well as present findings from Can-Fite's clinical programs to scientists and medical doctors attending the convention.
CANF: 2.44 (-0.21)
CANF Recent Posts: http://investorshangout.com/Can-Fite-Biopharm...ANF-88432/
CANF Can-Fite Biopharma Ltd Sponsore Recent Headline News
Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST
CANF: 2.44 (-0.21), JNJ: 108.54 (-0.37), IDRA: 2.50 (-0.08), DERM: 16.03 (unch), MRK: 59.28 (-0.09), PFE: 30.38 (+0.06), AZN: 74.17 (-0.03), AMGN: 161.31 (-1.11), GSK: 45.67 (-0.29), HSP: 57.69 (+0.38), NVS: 92.90 (+0.13), CELG: 107.32 (-0.53)
Can-Fite to Participate in BIO-Europe International Partnering Conference
PR Newswire - Thu Oct 30, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that the Company's CEO, Dr. Pnina Fishman and its Director of Business Development, Dr. Sari Fishman, will participate in approximately 40 scheduled one-on-one meetings with potential industry partners at BIO-Europe® in Frankfurt, Germany on November 3 to 5, 2014.
CANF: 2.44 (-0.21)
Ad Comm backs approval of secukinumab
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 6:32AM CDT
CANF: 2.44 (-0.21), JNJ: 108.54 (-0.37), IDRA: 2.50 (-0.08), DERM: 16.03 (unch), PFE: 30.38 (+0.06), AZN: 74.17 (-0.03), MRK: 59.28 (-0.09), AMGN: 161.31 (-1.11), HSP: 57.69 (+0.38), CELG: 107.32 (-0.53), NVS: 92.90 (+0.13)
Ad Comm meeting approaches for Novartis' psoriasis therapy candidate
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 10:46AM CDT
CANF: 2.44 (-0.21), JNJ: 108.54 (-0.37), IDRA: 2.50 (-0.08), DERM: 16.03 (unch), PFE: 30.38 (+0.06), AZN: 74.17 (-0.03), MRK: 59.28 (-0.09), AMGN: 161.31 (-1.11), HSP: 57.69 (+0.38), CELG: 107.32 (-0.53), NVS: 92.90 (+0.13)
Corcept Therapeutics (CORT) Jumps: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 8:32AM CDT
Corcept Therapeutics Incorporated (CORT) was a big mover last session, as the company saw its shares rise more than 6% on the day.
CANF: 2.44 (-0.21), AMPE: 3.37 (-0.26), CEMP: 14.03 (-0.02), CORT: 3.01 (-0.06)
Can-Fite CEO Dr. Pnina Fishman to Co-Chair and Present at the 19th World Congress on Advances in Oncology's Cancer Therapeutics Session
PR Newswire - Tue Oct 07, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced the Company's CEO, Dr. Pnina Fishman, will co-chair the Cancer Therapeutics session of the 19th World Congress on Advances in Oncology. The conference will take place in Athens, Greece, from October 9-11, 2014.
CANF: 2.44 (-0.21)
U.S. Patent and Trademark Office Issues Can-Fite Patent for CF102 in the Treatment of Liver Regeneration and Function Following Surgery
PR Newswire - Tue Sep 30, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced the United States Patent and Trademark Office has issued a patent to the Company which covers its drug candidate, CF102, in the treatment of liver regeneration and function following liver surgery. The issued patent # 8,846,635 is titled, "Method for inducing hepatocyte proliferation and uses thereof." Can-Fite has recently been granted a patent for this technology in Japan and the European Union.
CANF: 2.44 (-0.21)
Can-Fite Files June 30, 2014 Interim Financial Statements
PR Newswire - Wed Sep 17, 2:02PM CDT
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has filed its unaudited interim consolidated financial statements as of June 30, 2014 and an operating and financial review for such period with the U.S. Securities and Exchange Commission. The filing can be found on the company's website at www.canfite.com as well as on the SEC website at www.sec.gov.
CANF: 2.44 (-0.21)
Can Fite's Drug CF101 is Presented in Scientific Journal as One of Four Small Molecule Drugs for the Treatment of Psoriasis
PR Newswire - Wed Sep 17, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that an article titled, "New Drugs and Treatment Targets in Psoriasis," published in the peer-reviewed scientific journal Acta Derm Venereologica, cites the Company's CF101 as a potential treatment for psoriasis. The article was written by researchers at the Department of Dermato-allergology, Gentofte Hospital, University of Copenhagen, Denmark. To read the article in full, please visit: Acta Derm Venereologica.
CANF: 2.44 (-0.21)
Uveitis Therapeutics Pipeline Review, H2 2014 - 19 Companies & 30 Drug Profiles
M2 - Tue Sep 09, 8:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cv63wn/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - pSivida Corp. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Apitope International NV - Novartis AG - Pfizer Inc. - Enzo Biochem, Inc. - Can-Fite BioPharma Ltd. - XOMA Corporation - HanAll Biopharma Co., Ltd. - TxCell SA - Endocyte, Inc. - to-BBB technologies BV - Janssen Biotech, Inc. - Icon Bioscience, Inc. - Eleven Biotherapeutics - AbbVie Inc. - OncoNOx ApS - Panoptes Pharma Ges.m.b.H. Drug Profiles - sirolimus - adalimumab - fluocinolone acetonide - gevokizumab - secukinumab - CF-101 - triamcinolone acetonide - LFG-316 - B27-PD - triamcinolone acetonide - celecoxib - HL-036 - EC-1496 - PA-2612 - 2B3-201 - ATX-UV1 - ATX-UV2 - Stem Cell Therapy for Ophthalmic and Autoimmune Diseases - OX-1001 - P-13 - IBI-70090 - plastoquinone decyl triphenylphosphonium bromide - EC-1669 - lodamin - PP-001 - INV-17 - EBI-028 - Col-Treg - Small Molecules to Inhibit Kinase for Uveitis and IBD - Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Metabolic, Respiratory and Autoimmune Disorders For more information visit http://www.researchandmarkets.com/research/cv63wn/uveitis
CANF: 2.44 (-0.21), ECYT: 6.46 (+0.21), ENZ: 4.93 (+0.01), PFE: 30.38 (+0.06), ABBV: 63.69 (-0.16), XOMA: 4.00 (-0.04), NVS: 92.90 (+0.13)
Can-Fite BioPharma receives Japanese patent for liver regeneration clinical stage drug candidate CF102
M2 - Mon Sep 08, 5:27AM CDT
Biotechnology company Can-Fite BioPharma (NYSE MKT:CANF) (Tel Aviv:CFBI.TA) reported on Friday the receipt of the patent, titled 'Method for inducing hepatocyte proliferation and uses thereof', from the Japanese Patent Office.
CANF: 2.44 (-0.21)
Can-Fite Issued Japanese Patent for CF102 in the Treatment of Liver Regeneration and Function Following Surgery
PR Newswire - Fri Sep 05, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced the issuance of Patent No. 2010-529501, titled, "Method for inducing hepatocyte proliferation and uses thereof," by the Japanese Patent Office. The patent covers Can-Fite's clinical stage drug candidate, CF102, in the treatment of liver regeneration and function following liver surgery or other injury via inhibition of pro-apoptotic proteins, resulting in liver repair. A European Patent (No. 2227234) for this technology was issued earlier this year in the European Union.
CANF: 2.44 (-0.21)
Can-Fite posts lower loss of USD3.59m for first six months 2014
M2 - Wed Sep 03, 7:21AM CDT
Biotechnology company Can-Fite BioPharma (NYSE MKT:CANF) (Tel Aviv:CFBI.TA) on Tuesday declared a loss of USD3.59m for the six months ended 30 June 2014.
CANF: 2.44 (-0.21)
Can-Fite to Present at Rodman & Renshaw Global Investment Conference in New York City on September 9, 2014
PR Newswire - Wed Sep 03, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today the Company's CEO, Dr. Pnina Fishman, will present at the Rodman & Renshaw 16th Annual Global Investment Conference which will take place at the New York Palace Hotel in New York City on September 8th through 10th, 2014. Dr. Fishman is scheduled to present at 11.40 am on Tuesday, September 9th.
CANF: 2.44 (-0.21)
Can-Fite Reports First Six Months 2014 Results
PR Newswire - Tue Sep 02, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported financial results for the six months ended June 30, 2014 and updates on its clinical programs.
CANF: 2.44 (-0.21)
New Data Shows High Efficacy for Can-Fite's CF101 in Rheumatoid Arthritis and Psoriasis Patients
PR Newswire - Wed Aug 06, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today new data from a retrospective analysis of its autoimmune disease advanced trials that shows high efficacy of its orally bioavailable drug CF101.
CANF: 2.44 (-0.21)
Chronic Plaque Psoriasis - Pipeline Review, H1 2014
M2 - Wed Jul 30, 3:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dpkjk3/chronic_plaque) has announced the addition of the "Chronic Plaque Psoriasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Plaque Psoriasis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Plaque Psoriasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - AbGenomics International, Inc. - AbbVie Inc. - Actelion Ltd - Almirall, S.A. - ApoPharma Inc. - Biotest AG - Boehringer Ingelheim GmbH - Can-Fite BioPharma Ltd. - Eli Lilly and Company - GlaxoSmithKline plc - Incyte Corporation - Merck & Co., Inc. - Novartis AG - OPKO Health, Inc. - Pfizer Inc. - Sandoz Inc. For more information visit http://www.researchandmarkets.com/research/dp...nic_plaque
CANF: 2.44 (-0.21), OPK: 8.34 (-0.19), PFE: 30.38 (+0.06), MRK: 59.28 (-0.09), INCY: 70.82 (-0.24), LLY: 67.54 (-0.31), ABBV: 63.69 (-0.16), GSK: 45.67 (-0.29), NVS: 92.90 (+0.13)
Can-Fite CEO to Deliver Scientific Presentation and Serve on Expert Panel at Purines 2014 in Bonn, Germany on July 23-27, 2014
PR Newswire - Mon Jul 21, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today the Company's CEO and Chief Science Officer, Dr. Pnina Fishman, will participate in Purines 2014. The international conference on nucleotides, nucleosides and nucleobases, is to be held in Bonn, Germany, from July 23-27, 2014. Purines 2014 will bring together the leading international scientists in the field. At this year's conference aspects of the molecular and cellular biology of purinergic signaling will be covered as well as its role in the physiology and pathology of various organ systems and the development of novel strategies for drug development and therapy.
CANF: 2.44 (-0.21)
Can-Fite's CF102 Approved for Compassionate Use in Israel for Liver Cancer Patient
PR Newswire - Thu Jul 10, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Israeli Ministry of Health (MOH) has approved the use of its drug CF102 for a patient with hepatocellular carcinoma, the most common form of liver cancer, under the country's Compassionate Use Program. The program allows doctor-initiated single-patient access to investigational treatments for innovative or investigational products not yet registered in any country worldwide. Can-Fite has also previously received Orphan Drug Designation from the U.S. Food and Drug Administration for CF102 in the treatment of advanced hepatocellular carcinoma.
CANF: 2.44 (-0.21)
Can-Fite to Exhibit at Bio International Convention in San Diego on June 23 - 26, 2014
PR Newswire - Thu Jun 19, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today the Company will exhibit at the Bio International Convention in San Diego on June 23rd through 26th, 2014 at the Israel Office of the Chief Scientist's booth #611. The Company's CEO, Dr. Pnina Fishman and its Director of Business Development, Dr. Sari Fishman will conduct one-on-one meetings with potential partners, as well as present findings from Can-Fite's clinical programs to scientists and medical doctors attending the convention.
CANF: 2.44 (-0.21)
(0)
(0)Can-Fite Biopharma Ltd. (CANF) Stock Research Links
Scroll down for more posts ▼